Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

4

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Muscarinic acetylcholine receptor M1

4

Muscarinic acetylcholine receptor M2

4

Muscarinic acetylcholine receptor M3

4

Muscarinic acetylcholine receptor M4

4

Muscarinic acetylcholine receptor M5

4

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

4

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2004

4

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency

4

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

4

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

4

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Yamanouchi Pharmaceutical

4

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

4

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

4

FDA UNII

4

PUBCHEM

4

SMS_ID

3

ChEMBL

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

GENITO URINARY SYSTEM AND SEX HORMONES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

UROLOGICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY

1

OTHER UROLOGICALS, INCL. ANTISPASMODICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Alpha-adrenoreceptor antagonists

1

Urinary antispasmodics

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

3

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 4 of 4 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

SOLIFENACIN

A8910SQJ1U

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 2004

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Muscarinic acetylcholine receptor M3

Muscarinic acetylcholine receptor M2

Muscarinic acetylcholine receptor M1

Muscarinic acetylcholine receptor M4

Muscarinic acetylcholine receptor M5

Conditions:

Overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency

Solifenacin is a competitive muscarinic acetylcholine receptor antagonist. The binding of acetylcholine to these receptors, particularly the M3 receptor subtype, plays a critical role in the contraction of smooth muscle. By preventing the binding of ...

acetylcholine to these receptors, solifenacin reduces smooth muscle tone in the bladder, allowing the bladder to retain larger volumes of urine. It is FDA approved for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Common adverse reactions include constipation, Xerostomia. Inhibitors of CYP3A4 may increase the concentration of Solifenacin. Vice versa, CYP3A4 Inducers decrease concentration.

Solifenacin fumarate

25HF7HWP9L

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 2004

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Muscarinic acetylcholine receptor M3

Muscarinic acetylcholine receptor M2

Muscarinic acetylcholine receptor M1

Muscarinic acetylcholine receptor M4

Muscarinic acetylcholine receptor M5

Conditions:

Overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency

Solifenacin is a competitive muscarinic acetylcholine receptor antagonist. The binding of acetylcholine to these receptors, particularly the M3 receptor subtype, plays a critical role in the contraction of smooth muscle. By preventing the binding of ...

acetylcholine to these receptors, solifenacin reduces smooth muscle tone in the bladder, allowing the bladder to retain larger volumes of urine. It is FDA approved for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Common adverse reactions include constipation, Xerostomia. Inhibitors of CYP3A4 may increase the concentration of Solifenacin. Vice versa, CYP3A4 Inducers decrease concentration.

SOLIFENACIN TARTRATE

CCM244AP8R

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 2004

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Muscarinic acetylcholine receptor M3

Muscarinic acetylcholine receptor M2

Muscarinic acetylcholine receptor M1

Muscarinic acetylcholine receptor M4

Muscarinic acetylcholine receptor M5

Conditions:

Overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency

Solifenacin is a competitive muscarinic acetylcholine receptor antagonist. The binding of acetylcholine to these receptors, particularly the M3 receptor subtype, plays a critical role in the contraction of smooth muscle. By preventing the binding of ...

acetylcholine to these receptors, solifenacin reduces smooth muscle tone in the bladder, allowing the bladder to retain larger volumes of urine. It is FDA approved for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Common adverse reactions include constipation, Xerostomia. Inhibitors of CYP3A4 may increase the concentration of Solifenacin. Vice versa, CYP3A4 Inducers decrease concentration.

SOLIFENACIN SUCCINATE

KKA5DLD701

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 2004

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Muscarinic acetylcholine receptor M3

Muscarinic acetylcholine receptor M2

Muscarinic acetylcholine receptor M1

Muscarinic acetylcholine receptor M4

Muscarinic acetylcholine receptor M5

Conditions:

Overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency

Solifenacin is a competitive muscarinic acetylcholine receptor antagonist. The binding of acetylcholine to these receptors, particularly the M3 receptor subtype, plays a critical role in the contraction of smooth muscle. By preventing the binding of ...

acetylcholine to these receptors, solifenacin reduces smooth muscle tone in the bladder, allowing the bladder to retain larger volumes of urine. It is FDA approved for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Common adverse reactions include constipation, Xerostomia. Inhibitors of CYP3A4 may increase the concentration of Solifenacin. Vice versa, CYP3A4 Inducers decrease concentration.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1